In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Cara Therapeutics (CARA – Research Report), with a price target of $26.00. The company's shares closed last Tuesday at $10.06, close to its 52-week low of $9.63. According to TipRanks.com, Stringer is ranked 0 out of 5 stars with an average return of -25.0% and a 21.6% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Phathom Pharmaceuticals, and Lexicon Pharmaceuticals. Cara Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $26.00.
https://www.tipranks.com/news/blurbs/needham-thinks-cara-therapeutics-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Cara Therapeutics Charts.
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Cara Therapeutics Charts.